Ken Griffin Moon Lake Immunotherapeutics Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 11,500 shares of MLTX stock, worth $481,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,500

Previous 13,200 12.88%

Holding current value

$481,850

Previous $665,000 8.12%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$45.84 - $57.91 $6.24 Million - $7.88 Million	-136,105 Reduced 5.86%	2,186,866 $116 Million
Q3 2024 Nov 14, 2024	BUY	$40.15 - $55.4 $2.3 Million - $3.17 Million	57,276 Added 2.53%	2,322,971 $117 Million
Q2 2024 Aug 14, 2024	SELL	$38.43 - $48.6 $1.68 Million - $2.13 Million	-43,738 Reduced 1.89%	2,265,695 $99.6 Million
Q1 2024 May 15, 2024	BUY	$43.78 - $63.86 $13.2 Million - $19.2 Million	300,773 Added 14.97%	2,309,433 $116 Million
Q4 2023 Feb 14, 2024	SELL	$36.35 - $63.02 $935,503 - $1.62 Million	-25,736 Reduced 1.27%	2,008,660 $121 Million
Q3 2023 Nov 14, 2023	BUY	$48.35 - $61.26 $666,649 - $844,652	13,788 Added 0.68%	2,034,396 $116 Million
Q2 2023 Aug 14, 2023	SELL	$19.01 - $51.79 $17.2 Million - $46.8 Million	-902,830 Reduced 30.88%	2,020,608 $103 Million
Q1 2023 May 15, 2023	BUY	$11.03 - $23.7 $411,926 - $885,100	37,346 Added 1.29%	2,923,438 $62.5 Million
Q4 2022 Feb 14, 2023	BUY	$7.05 - $10.5 $1.41 Million - $2.1 Million	200,155 Added 7.45%	2,886,092 $30.3 Million
Q3 2022 Nov 14, 2022	SELL	$5.25 - $9.27 $87,801 - $155,031	-16,724 Reduced 0.62%	2,685,937 $21.4 Million

Others Institutions Holding MLTX

# of Institutions

136

Shares Held

58.1M

Call Options Held

124K

Put Options Held

96.9K

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.55B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account